Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Phase 2 trial data (published in New England Journal of Medicine, 2023 ): 24.2% average weight loss at 48 weeks with 12 mg dose 22.8% with 8 mg dose Placebo group lost 2.1% Most recent Phase 3 trial data (TRIUMPH-4, December 2025): 28.7% average weight loss at 68 weeks with 12 mg dose 26.4% with 9 mg dose 58.6% of participants on 12 mg achieved at least 25% weight loss 39.4% achieved at least 30% weight loss For context: These are the highest weight loss numbers reported in any clinical trial for a pharmacological obesity treatment
Sturm and Artz have an incredible record of success 99% of their clients stay out of jail and keep their license on first or second DUI offenses, and they win Not Guilty verdicts all charges dismissed in 90% of their DUI jury trials, even in cases involving prior convictions, accidents, high blood alcohol levels, and BAC test refusals
Accessed on June 17, 2024 at PlushCare content is reviewed by MDs, PhDs, NPs, nutritionists, and other healthcare professionals
Research shows that semaglutide users often lose about 1520% of their body weight, while those taking tirzepatide may see even greater results, with weight loss reaching 2025%
Additionally, preclinical metabolic models are often used to examine these mechanisms across multiple tissues involved in energy balance, including liver, adipose tissue, and skeletal muscle
At 1.25mg per injection, you are working with very small volumes
US$ 22.35
US$ 23.90
US$ 26.39
US$ 24.38
US$ 22.93
